Latest News

Nyrada says its PROTECT MI Phase 2a study of Xolatryp remains on track for completion in calendar 2027 and is moving through the staged rollout typical of first-in-patient cardiovascular studies.

Memphasys has announced a 12-month exclusive national supply agreement with Monash IVF Group for the Felix automated sperm selection system.

Melbourne-based Dimerix has granted Everest Medicines exclusive rights to commercialise DMX 200 for all indications, including Focal Segmental Glomerulosclerosis, in China, South Korea, and parts of Southeast Asia.

Entropy CEO Jason Carroll said, “The DSMB’s recommendation to progress to Cohort 2 without any protocol changes is an important milestone for the TRP-8803 program and provides independent validation of the favourable safety profile observed in Cohort 1.”

Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into the next phase of clinical and corporate catalysts.

Prescient Therapeutics has announced that Dr Rosalind Wilson will become its Chief Medical Officer, a move the clinical-stage oncology company says will strengthen its clinical and strategic capabilities as it advances multiple programs.

Andy Wong, Head of Innovation and Technology (Life and Health Sciences) at InvestHK, recently returned to Hong Kong after attending the AusMedtech Conference in Perth.

The survey found that 82 per cent of biotech companies six years and older agreed they would experience a significant impact. 36 respondents (61 per cent) said the proposed changes to the Capital Gains Tax would negatively affect them.

Australian cell therapy company Cartherics has announced that the Japanese Patent Office has issued a new patent for its off-the-shelf immune cell therapies.

CEO and Managing Director Dr David Foster said, “The expansion of our CRADA with USAMRIID and Geneva represents a major strategic milestone for Island and positions the Company to undertake the efficacy study prior to the pivotal study for Galidesivir.”

LTR Pharma has taken a decisive step toward bringing its rapid-acting intranasal erectile dysfunction treatment ROXUS to the United States by signing a binding term sheet with Shed Holdings, a US direct-to-consumer telehealth platform.

The company said the FDA correspondence represents a significant regulatory milestone because it completes the substantive review and moves the filing to the last administrative step before a decision.